The purpose of this study is to evaluate the efficacy of adding cusatuzumab to venetoclax plus azacitidine (VAC) compared to venetoclax plus azacitidine (VA) alone for patients with acute myeloid leukemia (AML).

Cusatuzumab is considered investigational which means it has not been approved by the U.S. Food and Drug Administration (FDA). Azacitidine and venetoclax are both FDA-approved.   

This is a randomized clinical research study examining an investigational treatment called CVN424 in patients with Parkinson's Disease (PD).

The purpose of this prospective randomized trial is to evaluate the serration angioplasty effect in below the knee arteries with calcified plaque when the Serranator Serration Angioplasty Balloon is used as compared to a conventional balloon angioplasty.

Conventional balloon angioplasty is a regularly used approach. The Serranator Angioplasty Nalloon is U.S. Food and Drug Administration (FDA) approved and commercially available.

The purpose of the trial is to find out if an investigational device called the “Boomerang Catheter System,” containing Boomerang Catheter and Boomerang Power Controller works for a new use in the leg and to monitor the safety in treating blockages in the arteries located behind and below the knee down to the small arteries located at the joint of the leg and foot in patients suffering from low blood flow to the lower leg.

The purpose of this research is to assess the continued safety and efficacy of the Esprit BTK system, which was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of narrowed arteries below the knee in patients with Chronic Limb-Threatening Ischemia (CLTI).

Participants may enroll in the study if this stent is used during their procedure. 

Study participation will last for three years, with follow-up visits (after the procedure) at 30 days, 90 days, 180 days, 1 year, 2 years, and 3 years.

The purpose of this study is to collect data on the use of commercially approved Boston Scientific drug-eluting devices used to treat peripheral vascular disease (PAD) to understand how these devices are being used in a routine hospital setting. We hope to potentially improve patient outcomes in the future as well as to understand how patient outcomes compare across diverse patient populations. The study data will also be used to continue monitoring the safety of these devices.

This clinical trial is designed for men and women with stage 4 squamous and non-squamous (NSCLC) who have not received prior systemic therapy for the advanced disease.
   
The purpose of this study is to evaluate the safety and tolerability of EIK1001 with pembrolizumab and chemotherapy in participants with histologically confirmed Stage 4 non-squamous or squamous NSCLC.

This clinical trial is for adults who have a brain tumor (glioblastoma) that has gotten worse despite first treatment and for whom additional surgery and chemotherapy are being recommended to treat their tumor.
   

This clinical trial is for men and women who have been diagnosed with clonal cytopenias of uncertain significance (CCUS) that is clinically significant.

The purpose of this study is to learn whether luspatercept is successful in improving blood counts in patients with clonal cytopenias of uncertain significance (CCUS). Luspatercept is a U.S. Food and Drug Administration (FDA) -approved drug for myelodysplastic syndrome (MDS) but is not approved for CCUS.

The purpose of this study is to evaluate the safety and effectiveness of the investigational Stryker Citadel Embolization Device for use in the treatment of patients with an aneurysm in the brain. A brain (cerebral) aneurysm is a bulging, weak area in the wall of an artery that supplies blood to the brain.

This device is an investigational device that has not been approved by the U.S. Food & Drug Administration (FDA) for treatment of this type of aneurysm.